annual meeting program - American Society of Clinical Oncology

Sunday, June 6, 2010
Brd. 15D Oncologically endoscopic nasopharyngectomy for T1/T2a and selected
T2b/T3 nasopharyngeal malignancies with nasopharynx resurfaced with
posterior pedicle nasal mucoperiosteum flap. (Abstract #5574)
M. Chen
Brd. 15E A comparison between surgery plus radiotherapy and exclusive
chemoradiation therapy regimes in oral and oropharyngeal cancer: Longterm
functional and psychological impact. (Abstract #5575)
M. Airoldi, M. Garzaro, L. Raimondo, G. Pecorari, C. Giordano
Brd. 15F Chemotherapy-enhanced accelerated radiotherapy for intermediate-volume
hypopharyngeal cancer. (Abstract #5576)
M. Kawashima, R. Hayashi, M. Tahara, T. Ogino
Brd. 15G An open, multicenter clinical study on cetuximab combined with intensity
modulated radiotherapy (IMRT) plus concurrent chemotherapy in
nasopharyngeal carcinoma (NPC): Preliminary report. (Abstract #5577)
T. Lu, C. Zhao, C. Chen, L. Gao, J. Lang, J. Pan, C. Hu, F. Jin, R. Wang, C. Xie
Brd. 15H Competing mortality in advanced head and neck cancer: A population-based
study. (Abstract #5578)
B. S. Rose, S. K. Nath, S. Lu, L. K. Mell
Brd. 16A Functional outcomes after cisplatin (C)-based concurrent chemoradiation
(CCRT) in patients (pts) with human papillomavirus (HPV)-related squamous
cell carcinoma of the orophrarynx (SCCOP). (Abstract #5579)
C. P. Rodriguez, D. J. Adelstein, L. A. Rybicki, J. P. Saxton, J. Scharpf, B. Burkey,
B. J. Wood, P. D. Knott, A. P. Hoschar, D. I. Ives
Brd. 16B Multicenter randomized phase II trial of combined radiotherapy and cisplatin
with or without erlotinib in patients with locally advanced squamous cell
carcinoma of the head and neck (SCCAHN): Preliminary toxicity results.
(Abstract #5580)
D. N. Hayes, L. E. Raez, A. K. Sharma, M. A. Papagikos, F. Yunus,
U. Parvathaneni, K. D. Eaton, N. Futran, S. G. Wallace, R. Martins
Brd. 16C Toxicity and one-year tumor control with induction chemotherapy and
bioradiotherapy for locally advanced unresectable head and neck cancer.
(Abstract #5581)
C. Mercke, H. Haugen, G. Adell, F. Costa-Svedman, J. Nyman, G. Wickart-
Johansson, H. Sjödin
Brd. 16D Long-term treatment outcome of nasopharyngeal carcinoma (NPC) using
intensity-modulated radiotherapy (IMRT). (Abstract #5582)
M. K. Kam, S. Leung, K. Yu, A. D. King, R. M. Chau, K. Cheung, B. Ma, E. P. Hui,
A. T. Ahuja, A. T. Chan
Brd. 16E Postoperative adjuvant chemoradiotherapy versus radiotherapy alone for
head and neck squamous cell carcinoma: A meta-analysis evaluating the role
of chemotherapy schedules. (Abstract #5583)
G. A. Viani, S. L. Afonso, L. A. Ramos, V. Afonso, E. Stefano
Brd. 16F Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN):
First overview of complete data set. (Abstract #5584)
P. M. Harari, A. Y. Chen, W. J. Curran Jr., A. S. Garden, B. A. Murphy, S. J. Wong,
L. A. Bellm, M. Schwartz, C. Schneider, K. Ang
Brd. 16G Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN):
Findings related to the oropharynx. (Abstract #5585)
S. J. Wong, A. Y. Chen, W. J. Curran Jr., A. S. Garden, P. M. Harari, B. A. Murphy,
L. A. Bellm, M. Schwartz, K. Ang
Brd. 16H Phase I trial of combination sorafenib and tipifarnib: The experience in
advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer
(MTC). (Abstract #5586)
M. E. Cabanillas, R. Kurzrock, S. I. Sherman, A. M. Tsimberidou, S. Waguespack,
A. Naing, N. Busaidy, R. Gagel, J. J. Wright, D. S. Hong
205
SUNDAY